CannabisNewsWire
Editorial Coverage: With the looming legalization of
marijuana in California slated for next month and Canada
preparing for legal recreational use July 2, 2018, it is no
surprise the North American Marijuana Index is at record highs, up
roughly 67 percent
since late October. The recent $22.6 billion forecast for the
U.S. market by 2021 from leading analyst Arcview, combined with
conservative estimates from Canada’s Parliamentary Budget Office of
around $6.2 billion by next year for the Canadian market, is
helping to fuel a massive influx of capital into the sector.
Particularly attractive are innovators like biopharma developer
InMed
Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF), which
has a compelling biosynthesis technology that will allow the
company to manufacture bio-identical cannabinoids of every
naturally occurring ones in-house, without the need for plant
feedstock. Robust, high-yield and cost-effective biosynthesis
technology like this could eventually acquire substantial market
share that is currently held by some of today’s leading medical
marijuana producers, such as Aurora Cannabis, Inc.
(TSX:ACB) (OTCQB:ACBFF), Canopy Growth Corp. (TSX:WEED)
(OTC:TWMJF), Aphria, Inc. (TSX:APH) (OTC:APHQF), and
Hydropothecary Corp. (TSX.V:THCX) (OTC:HYYDF).
With a market cap of around $102 million and a strong pipeline
of novel, rapidly developing cannabinoid-based drug therapies,
shares of InMed
Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF) are up
well over 450
percent year to date. The company’s biosynthesis process, while
revolutionary in the application of manufacturing cannabinoids, is
fundamentally based on a tried and tested methodology used
extensively throughout multiple industrial applications. For
example, bacteria or yeast-based systems are currently employed to
make pharmaceuticals like biosynthesized insulin used daily by
millions of diabetics worldwide. The only thing that may be more
attractive to investors than the company’s potentially
disruptive cannabinoid biosynthesis technology is the actual
drug development
pipeline, which currently spans areas from dermatology (INM-750
for Epidermolysis Bullosa) and ocular (INM-085 for glaucoma), to
the enormous pain management market (INM-405).
InMed recently filed a
provisional patent application in the United States for INM-405
and other unique cannabinoid-based topical pain treatment
compositions, directly addressing a pain management market on track
to hit upward of $77.1 billion by
2023, running at a 4 percent CAGR. The need for alternative
pain management therapies is demonstrated by the United States’
$504 billion
nationwide opioid crisis.
In a press release announcing the patent, InMed Chief Scientific
Officer Dr. Sazzad Hossain, a co-inventor of the patent, was keen
to point out how there is “a significant need in the field of
analgesia” for a product like INM-405, which can treat pain via a
topical route of administration, and thus “reduce systemic exposure
and any associated side effects.”
InMed’s ingenious use of genetically engineered microorganisms
to produce cannabinoids not only opens the gates for
industrial-scale manufacturing of naturally occurring cannabinoids,
it provides commercially viable access for the first time in
history to the rarest and most sought-after ones. The
sophistication of InMed’s biosynthesis platform for drug
engineering is evident from examples like the ocular hydrogel
formulation being developed in conjunction with the University of
British Columbia. The company recently
demonstrated a first of its kind hydrogel-mediated cannabinoid
nanoparticle offering, which uses a unique tissue-specific
delivery vehicle that forms a thin, uniform, gel-like ‘lens’ over
the cornea, via the natural reflex of blinking.
Eric A. Adams, president and CEO of InMed noted specifically how
the aforementioned nanoparticle hydrogel study offers investors, as
well as industry participants interested in the company’s
technology, “further validation of InMed's capabilities in moving
the science of cannabinoid pharmaceuticals forward.”
Adams elaborated, explaining that such data, in conjunction with
the company’s renowned scientific team, collaborators, rapidly
expanding patent portfolio and list of publications, as well as
ongoing R&D efforts — all added up to an unmistakably serious
demonstration of the company’s “depth of know-how” and supports
InMed’s “trajectory to becoming an industry leader.”
InMed has been making significant progress leveraging its
biosynthesis technology to advance its growing pipeline, and the
overall R&D effort has been significantly enhanced by the
company’s proprietary drug/disease targeting bioinformatics
assessment tool. These kinds of finer details about the
company’s capabilities are likely a large reason why InMed has
generated such a great deal of market buzz, with TheSeedInvestor.com putting the company as one of the
“5 Cannabis Biotech Stocks to Watch.”
“Extracting cannabinoids for medicinal applications using an
agriculture-based model involves a lengthy, expensive and
labor-intensive process of planting, growing, harvesting,
extracting and purifying. To avoid the shortcomings of an
agricultural approach, several biotechs have turned to chemical
processes to produce synthetic cannabinoids that can deliver
consistent quality, thereby overcoming some of these concerns and
increasing their prospects of gaining FDA approval. However,
synthetic production can be expensive and can present potential
safety issues. It is difficult to synthesize compounds that are
identical to their natural counterparts, and the slightest
structural variations can affect the quality and safety of the
finished product,” writes the sector-focused news outlet (http://nnw.fm/rrmO3).
The Seed Investor also provides a rundown of the sector’s top
performers of last year, showcasing short-term gains of as much as
a whopping 1,600 percent in some cases, most of which are up 100 to
200 percent or more year to date (http://cnw.fm/YJu5Q). The Seed Investor has its finger
on the pulse of the ongoing process of cannabis legalization taking
place throughout the U.S. and Canada and is dedicated to delivering
the best actionable intelligence on this potential $100 billion by
2020 industry, where investors can look to nail down opportunities
of 1,900 percent plus gains or more.
Another cannabis industry market mover is Aurora
Cannabis, Inc. (TSX:ACB) (OTCQB:ACBFF), which gained ,419
percent between June 2015 and November of last year, during which
period this Canadian medical marijuana producer and distributor
received its license to sell. One of only 35 currently licensed
producers in Canada, this $2.54 billion market cap producer boasts
the lowest cost-per-gram in the country and is the only producer in
Alberta, where the company’s rurally-located 55,200 square foot
facility has access to fresh mountain-fed water, as well as low
corporate tax and power rates. With a share price that is up over 210 percent
year to date (as of the December 15 close at $5.58 per share),
Aurora was the first Access to Cannabis for Medical Purposes
Regulations (ACMPR) applicant to construct a purpose-built,
state-of-the-art facility and chose a location supremely suited for
long-term growth. The company has another 40,000-square-foot
facility in Quebec and is currently constructing a gigantic 800,000
sq. ft. facility at the Edmonton International Airport.
Aurora is one of many Canadian producers who could greatly
benefit from InMed’s consistently high-purity, pharmaceutical-grade
biosynthesized product.
Canopy Growth Corp. (TSX:WEED) (OTC:TWMJF) saw
gains of 1,090 percent between August 2015 and November 2016, and
is currently up 95.53 percent
year to date (as of the December 15 close at $15.33 per share),
with a market cap of some $2.96 billion. Fortune 500 producer and
marketer of beer, wine and spirits, Constellation Brands
(NYSE:STZ), known for iconic brands like Corona beer and Svedka
vodka, recently purchased a nearly 10 percent stake in Canopy
Growth. This leading diversified purveyor of dried, oil, and
softgel cannabis products, has become somewhat synonymous with the
industry itself via brands like Bedrocan and Tweed, the most
recognized marijuana production brand in the world. The company is
superbly poised to benefit alongside other large licensed producers
under the forthcoming Canadian regulatory regime. Particularly in
Canada’s largest province, Ontario, where Canopy has its massive
40-acre, 500,000-square-foot campus.
Aphria (TSX:APH) (OTC:APHQF) rose 967 percent
starting just shortly after its IPO, from February 2015 to November
2016, and is currently up nearly 182
percent year to date (as of the December 15 close at $11.14 per
share), with a $1.7 billion market cap. The company prides itself
on producing high-quality, safe and pure pharmaceutical-grade
medical cannabis. Aphria hit a big milestone recently with receipt
of a key Dealer's License from the Canadian government, allowing
the company to possess, sell and transport medical cannabis oil and
resin to hungry international markets. The company is progressing
nicely with the four-part expansion of its fully-funded Ontario
facility, which will soon tout a greenhouse footprint of an
astonishing one million square feet. This new capacity will bring
Aphira’s production up to an estimated 220,000 pounds plus per year
of high-quality cannabis, which will be produced at one of the
lowest costs in the industry today.
Hydropothecary Corp. (TSX.V:THCX) (OTC:HYYDF)
is up nearly 116
percent year to date (as of the December 15 close at $3.06 per
share), with a market cap of roughly $271 million. And shares of
this ACMPR licensed producer located in Quebec are up over 242
percent since mid-July this year, an uptrend period beginning
shortly after the upsize of the company’s $25 million bought deal
private placement with Canaccord Genuity (OTC:CCORF).
Hydropothecary is one of only two licensed producers in Quebec and
has an enviable market position with innovative products like the
company’s Decarb Micro THC and Decarb Micro CBD ready-to-consume,
activated medical marijuana powders. Priced at just $3 a gram,
Decarb is some of the highest quality, lowest cost premium cannabis
on the market and provides a much sought after alternative to
smoking, vaping, or cannabis oils.
The soaring stock prices of high value operators in this nascent
industry may be just the beginning of the bull market for pot
stocks, as truly substantial markets like California and Canada
come online via blanket recreational use legalization. And while
the obvious foreground plays like plant producers who are focused
on the medical market (until the recreational one becomes viable)
make a lot of sense, the biotechs are arguably where the long-haul
profit taking will most likely eventuate for a variety of reasons.
A company like InMed is a triple play here: with scalable
high-capacity biosynthesis capabilities allowing them to bypass the
growers, a significant R&D capability and associated pipeline
of developing cannabinoid therapies, as well as the raw licensing
potential that is inherent in the company’s proprietary
biosynthesis and bioinformatics technology.
For more information on InMed Pharmaceuticals, please visit:
InMed
Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
CannabisNewsBreaks that summarize corporate news and
information, (3) enhanced press release services, (4) social media
distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news
and content distribution company with an extensive team of
contributing journalists and writers, CNW is uniquely positioned to
best serve private and public companies that desire to reach a wide
audience of investors, consumers, journalists and the general
public. CNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, CNW brings
its clients unparalleled visibility, recognition and brand
awareness. CNW is where news, content and information converge.
Receive Text Alerts
from CannabisNewsWire: Text "Cannabis" to
21000
For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News
Please see full terms of use and disclaimers on the
CannabisNewsWire website applicable to all content provided by CNW,
wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. FN Media
Group (FNM) is a third-party publisher and news dissemination
service provider, which disseminates electronic information through
multiple online media channels. FNM is NOT affiliated with CNW or
any company mentioned herein. The commentary, views and opinions
expressed in this release by CNW are solely those of CNW and are
not shared by and do not reflect in any manner the views or
opinions of FNM. Readers of this Article and content agree that
they cannot and will not seek to hold liable CNW and FNM for any
investment decisions by their readers or subscribers. CNW and FNM
and their respective affiliated companies are a news dissemination
and financial marketing solutions provider and are NOT registered
broker-dealers/analysts/investment advisers, hold no investment
licenses and may NOT sell, offer to sell or offer to buy any
security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, CNW, FNM, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer's filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer's securities, including, but not
limited to, the complete loss of your investment.
CNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS
RELEASE.
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words
such as "may", "future", "plan" or "planned", "will" or "should",
"expected," "anticipates", "draft", "eventually" or "projected".
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company's annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and CNW and FNM undertake no
obligation to update such statements.
Source:
CannabisNewsWire
Contact:
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
Canopy Growth (TSX:WEED)
Historical Stock Chart
From Aug 2024 to Sep 2024
Canopy Growth (TSX:WEED)
Historical Stock Chart
From Sep 2023 to Sep 2024